SETD2 and hepatocellular carcinoma: MAPKAPK5-AS1/PLAGL2/HIF-1 α signaling pathway was found to drive the progression of HCC and MAPKAPK5-AS1 might be a novel therapeutic target (Wang et al., 2021a).